Current surfactant use in premature infants

Clinics in Perinatology

Volumn 28, Issue 3, 2001, Pages 671-694

  Suresh, Gautham K ^a   Soll, Roger F ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUCINACTANT; LUNG SURFACTANT; LUNG SURFACTANT EXTRACT; LUSUPULTIDE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; PLACEBO; PUMACTANT; SINAPULTIDE; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; SURFACTANT PROTEIN D; SURFACTANT TA; SURFAXINE; UNCLASSIFIED DRUG;

BRADYCARDIA; BRAIN HEMORRHAGE; CLINICAL TRIAL; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; HYPOXIA; LUNG CIRCULATION; LUNG DYSPLASIA; LUNG HEMORRHAGE; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN MORTALITY; PNEUMOTHORAX; PREMATURITY; PRIORITY JOURNAL; REVIEW; TACHYCARDIA; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

EID: 0034837374     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-5108(05)70112-3     Document Type: Article

References (169)

1. Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant
2. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: A randomised trial
3. Lung volume and pulmonary blood flow measurements following exogenous surfactant
4. Clinical trial of survanta versus exosurf in infants <1500 g with respiratory distress syndrome
5. Surfactant deficiency in hyaline membrane disease: The story of discovery
6. Surface properties in relation to atelectasis and hyaline membrane disease
7. Immunogenicity and immunomodulatory activity of bovine surfactant (SF-RI 1)
8. Cerebral blood flow and plasma hypoxanthine in relation to surfactant treatment
9. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome
10. Use of surfactant for prophylaxis versus rescue treatment of respiratory distress syndrome: Experience from an Italian-Bulgarian trial
11. Prophylaxis of respiratory distress syndrome by treatment with modified porcine surfactant at birth: A multicentre prospective randomized trial
12. Effect of single dose surfactant on pulmonary function
13. Pulmonary mechanics and energetics in preterm infants who had respiratory distress syndrome treated with synthetic surfactant
14. Therapeutic use of surfactant in neonatal respiratory distress syndrome: Correlation between pulmonary X-ray changes and clinical data
15. Exosurf rescue surfactant improves high ventilation-perfusion mismatch in respiratory distress syndrome
16. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs
17. Comparison of infasurf (calf lung surfactant extract) to survanta (beractant) in the treatment and prevention of respiratory distress syndrome
18. Pulmonary haemodynamics after surfactant replacement in severe neonatal respiratory distress syndrome
19. Ventilation-perfusion relationships in preterm infants after surfactant treatment
20. Chest position and pulmonary deposition of surfactant in surfactant depleted rabbits
21. Surfactant proteins and anti-surfactant antibodies in sera from infants with respiratory distress syndrome with and without surfactant treatment
22. Pulmonary mechanics in ventilated preterm infants with respiratory distress syndrome after exogenous surfactant administration: A comparison between two surfactant preparations
23. Neonatal pulmonary ischemia: Clinical and physiological studies
24. Findings on chest radiographs after prophylactic pulmonary surfactant treatment of premature infants
25. Surface tension of lung extracts
26. Factors influencing the clinical response to surfactant replacement therapy in babies with severe respiratory distress syndrome
27. Double-blind, randomized trial of one versus three prophylactic doses of synthetic surfactant in 826 neonates weighing 700 to 1100 grams: Effects on mortality rate
28. Double-blind developmental evaluation at 1-year corrected age of 597 premature infants with birth weights from 500 to 1350 grams enrolled in three placebo-controlled trials of prophylactic synthetic surfactant
29. Surfactant administration to the human fetus in utero: A new approach to prevention of neonatal respiratory distress syndrome (RDS)
30. Double-blind 1-year follow-up of 1540 infants with respiratory distress syndrome randomized to rescue treatment with two doses of synthetic surfactant or air in four clinical trials
31. Effects of exogenous surfactant therapy on dynamic compliance during mechanical breathing in preterm infants with hyaline membrane disease
32. Pulmonary follow-up 2.5 years after a randomized, controlled, multiple dose bovine surfactant study of preterm newborn infants
33. Cerebral blood flow velocity changes after rapid administration of surfactant
34. The pulmonary surfactant system: Biochemical and clinical aspects
35. Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: Experiences in a developing country
36. Surfactant nebulization versus instillation during high frequency ventilation in surfactant-deficient rabbits
37. Radiological changes after therapeutic use of surfactant in infants with respiratory distress syndrome
38. Changing mortality and causes of death in infants 23-27 weeks' gestational age
39. Two-year follow-up of infants enrolled in a randomized trial of surfactant replacement therapy for prevention of neonatal respiratory distress syndrome
40. Single- versus multiple-dose surfactant replacement therapy in neonates of 30 to 36 weeks' gestation with respiratory distress syndrome
41. Bovine surfactant replacement therapy: A comparison of 2 retreatment strategies in premature infants with RDS
42. Bovine surfactant replacement therapy in neonates of less than 30 weeks' gestation: A randomized controlled trial of prophylaxis versus treatment
43. Cerebral hemodynamic effects of treatment with modified natural surfactant investigated by near infrared spectroscopy
44. Comparison of prophylaxis and rescue treatment with curosurf in neonates less than 30 weeks' gestation: A randomized trial
45. Economic consequences of surfactant therapy
46. Surfactant aerosol treatment of respiratory distress syndrome in the spontaneously breathing premature rabbit
47. From bubbles to babies: The evolution of surfactant replacement therapy
48. Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant
49. Early or selective surfactant (colfosceril palmitate, exosurf) for intubated babies at 26 to 29 weeks gestation: A European double-blind trial with sequential analysis
50. Effects of surfactant therapy on outcome of infants with birth weights of 600 to 750 grams
51. Lysis of red blood cells and alveolar epithelial toxicity by therapeutic pulmonary surfactants
52. Nebulisation of surfactants in an animal model of neonatal respiratory distress
53. Artificial surfactant in hyaline membrane disease
54. Clinical events in association with timing of intraventricular hemorrhage in preterm infants
55. Pulmonary function at school-age in surfactant-treated preterm infants
56. Pulmonary hemorrhage risk in infants with a clinically diagnosed patent ductus arteriosus: A retrospective cohort study
57. Early versus late surfactant treatment in preterm infants of 27 to 32 weeks' gestational age: A multicenter controlled clinical trial
58. Pulmonary surfactant in health and human lung diseases: State of the art
59. Surface tension as a factor in the resistance of neonatal lungs to aeration
60. Prophylactic surfactant for preterm infants
61. Acute effects of instillation of surfactant in severe respiratory distress syndrome
62. Association between neonatal care practices and efficacy of exogenous human surfactant: Results of a bicenter randomized trial
63. Exogenous human surfactant for treatment of severe respiratory distress syndrome: A randomized prospective clinical trial
64. A theoretical study of surfactant and liquid delivery into the lung
65. Changes in pulmonary artery pressure in infants with respiratory distress syndrome following treatment with exosurf
66. Changes in pulmonary artery pressure during the acute phase of respiratory distress syndrome treated with three different types of surfactant
67. The influence of the wider use of surfactant therapy on neonatal mortality among blacks and whites
68. Cerebroelectrical depression following surfactant treatment in preterm neonates
69. Factors influencing morbidity and mortality in infants with severe respiratory distress syndrome treated with single or multiple doses of a natural porcine surfactant
70. Effects of surfactant therapy on outcome of extremely premature infants
71. A European multicenter randomized controlled trial of single dose surfactant therapy for idiopathic respiratory distress syndrome
72. Decreasing mortality associated with the introduction of surfactant therapy: An observational study of neonates weighing 601 to 1300 grams at birth
73. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome
74. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome
75. Effects of ventilation style on surfactant metabolism and treatment response in preterm lambs
76. Pulmonary surfactant therapy
77. Mechanisms initiating lung injury in the preterm
78. Surfactant metabolism
79. Surfactant and acute lung injury
80. Surfactant and pulmonary blood flow distributions following treatment of premature lambs with natural surfactant
81. Pulmonary hemodynamics after synthetic surfactant replacement in neonatal respiratory distress syndrome
82. Surfactant: Evolving issues
83. High-versus low-threshold surfactant retreatment for neonatal respiratory distress syndrome
84. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation
85. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation
86. Comparison of two strategies for surfactant prophylaxis in very premature infants: A multicenter randomized trial
87. Surfactant replacement therapy in premature babies with respiratory distress syndrome: Factors affecting the response to surfactant and comparison of outcome from 1982-86 and 1987-91
88. A prospective, randomized trial of early versus late administration of a single dose of surfactant-TA
89. Prognostic value of the immediate response to surfactant
90. Randomized trial comparing natural and synthetic surfactant: Increased infection rate after natural surfactant?
91. Pulmonary surfactant proteins
92. Trend in mortality from respiratory distress syndrome in the United States, 1970-1995
93. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome
94. Changes in EEG, systemic circulation and blood gas parameters following two or six aliquots of porcine surfactant
95. Economic impact of two rescue doses of exosurf neonatal in 700-1350 gram infants
96. Surfactant replacement therapy: Impact on hospital charges for premature infants with respiratory distress syndrome
97. Synthetic surfactant for rescue treatment of respiratory distress syndrome in premature infants weighing from 700 to 1350 grams: Impact on hospital resource use and charges
98. Pulmonary surfactant: A historical perspective of how it came to be used in the treatment of respiratory distress syndrome in the neonate
99. Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity
100. Comparative efficacy of exosurf and survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity
101. Follow up of premature babies treated with artificial surfactant (ALEC)
102. Cost implications of different approaches to the prevention of respiratory distress syndrome
103. Randomized trial examining cerebral haemodynamics following artificial or animal surfactant
104. Comparison of two methods of surfactant administration and the effect on dosing-associated hypoxemia
105. Bronchiolar epithelial lesions induced in the premature rabbit neonate by short periods of artificial ventilation
106. Outcome following pulmonary haemorrhage in very low birthweight neonates treated with surfactant
107. Properties, function and origin of the alveolar lining layer
108. A randomized trial comparing exosurf versus survanta in the treatment of neonatal RDS
109. Effect of neonatal surfactant therapy on lung function at school age in children born very preterm
110. In utero surfactant administration to preterm human fetuses using endoscopy
111. Cost effects of surfactant therapy for neonatal respiratory distress syndrome
112. Neonatal mortality rate: Is further improvement possible?
113. The role of surfactant associated proteins
114. Pulmonary hemorrhage and exogenous surfactant therapy: A metaanalysis
115. Racial differences in respiratory-related neonatal mortality among very low birth weight infants
116. Different ventilation strategies alter surfactant responses in preterm rabbits
117. A 2-year follow up of babies enrolled in a European multicentre trial of porcine surfactant replacement for severe neonatal respiratory distress syndrome: Collaborative European Multicentre Study Group
118. Principles of surfactant replacement
119. Microaerosol administration of synthetic dipalmitoyl-L-lecithin in the respiratory distress syndrome: A preliminary report
120. Comparison of clinical responses to natural and synthetic surfactants
121. Surfactant replacement therapy improves ventilation inhomogeneity in infants with respiratory distress syndrome
122. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g
123. Surfactant substitution in ventilated very low birth weight infants: Factors related to response types
124. Pulmonary distribution and efficacy of exogenous surfactant in lung-lavaged rabbits are influenced by the instillation technique
125. Modified bovine surfactant (survanta) versus a protein-free surfactant (exosurf) in the treatment of respiratory distress syndrome in preterm infants: A pilot study
126. Decreased surfactant dose-response after delayed administration to preterm rabbits
127. One-year follow-up of 273 infants with birth weights of 700 to 1100 grams after prophylactic treatment of respiratory distress syndrome with synthetic surfactant or air placebo
128. Acute effects of synthetic surfactant replacement on pulmonary blood flow in neonatal respiratory distress syndrome
129. Hemodynamic prediction of complications in neonatal respiratory distress syndrome
130. School-age follow-up of prophylactic versus rescue surfactant trial: Pulmonary, neurodevelopmental, and educational outcomes
131. Pump administration of exogenous surfactant: Effects on oxygenation, heart rate, and chest wall movement of premature infants
132. The effects of surfactant on haemodynamics in hyaline membrane disease
133. Surfactant administration and the cerebral circulation
134. Acute changes in cerebral oxygenation and cerebral blood volume in preterm infants during surfactant treatment
135. Radiological analysis of hyaline membrane disease after exogenous surfactant treatment
136. A randomized comparison of surfactant dosing via a dual-lumen endotracheal tube in respiratory distress syndrome
137. A simplified surfactant dosing procedure in respiratory distress syndrome: The side-hole randomized study
138. Multiple versus single dose natural surfactant extract for severe neonatal respiratory distress syndrome
139. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome
140. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants
141. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants
142. Surfactant treatment of the very preterm infant
143. Synthetic surfactant for respiratory distress syndrome in preterm infants
144. Radiographic findings associated with surfactant treatment
145. Cost effectiveness of beractant in the prevention of respiratory distress syndrome
146. Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants
147. Use of natural surfactants to prevent and treat respiratory distress syndrome
148. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome
149. Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: Single versus multiple doses of curosurf
150. Surfactant replacement: Immunological considerations
151. Early versus delayed neonatal administration of a synthetic surfactant - The judgment of OSIRIS
152. Pulmonary hemorrhage: Clinical course and outcomes among very low-birth- weight infants
153. Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: A randomised controlled trial
154. Distribution of surfactant and ventilation in surfactant-treated preterm lambs
155. Outcome at twelve months of adjusted age in very low birth weight infants with lung immaturity: A randomized, placebo-controlled trial of human surfactant
156. Neurodevelopmental and respiratory outcome in early childhood after human surfactant treatment
157. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome
158. Neue auffassungen uber einen grundbegriff der atemmechanik. Die retraktionskraft der lunge, abhangig von der oberflachenspannung in den alveolen
159. School-age follow-up of a single-dose prophylactic surfactant cohort
160. Prediction of the acute response to surfactant therapy by pulmonary function testing
161. Pulmonary functional outcome at one year of age in infants treated with natural porcine surfactant at birth
162. Porcine surfactant replacement therapy in newborns of 25-31 weeks' gestation: A randomized, multicentre trial of prophylaxis versus rescue with multiple low doses
163. Health and developmental outcomes of a surfactant controlled trial: Follow-up at 2 years
164. Failure to detect surfactant protein-specific antibodies in sera of premature infants treated with survanta, a modified bovine surfactant
165. Porcine-derived lung surfactant: A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (curosurf) in neonatal respiratory distress syndrome
166. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome
167. Respiratory function at follow-up after neonatal surfactant replacement therapy
168. Comparison of three dosing procedures for administration of bovine surfactant to neonates with respiratory distress syndrome
169. Treatment investigational new drug experience with survanta (beractant)